Hyperion Therapeutics To Present At The Leerink Swann Rare Disease Day

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Swann Rare Disease Day on Wednesday, October 2 at 9:20 a.m. ET.

Donald J. Santel, chief executive officer will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm .

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns and markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For more information, please visit www.hyperiontx.com.
CONTACT: Sylvia Wheeler, Investor Relations         (650) 745-7834         sylvia.wheeler@hyperiontx.com

If you liked this article you might like

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Ireland’s Horizon Pharma Makes $3 Billion Hostile Bid for Depomed

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Stock Markets Soar on Trifecta of Good News

Stock Markets Soar on Trifecta of Good News

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion